BioNTech shares are trading lower after the company and Pfizer announced top-line results from their Phase 3 clinical trial to evaluate the combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals between 18 and 64. The Phase 3 trial did not meet one of the two primary immunogenicity objectives.
Portfolio Pulse from Benzinga Newsdesk
BioNTech shares are trading lower after the company and Pfizer announced that their Phase 3 clinical trial for a combined mRNA vaccine against influenza and COVID-19 did not meet one of the two primary immunogenicity objectives.
August 16, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioNTech shares are trading lower after the company and Pfizer announced that their Phase 3 clinical trial for a combined mRNA vaccine against influenza and COVID-19 did not meet one of the two primary immunogenicity objectives.
The failure to meet one of the primary immunogenicity objectives in a Phase 3 trial is a significant setback for BioNTech, likely leading to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer, in collaboration with BioNTech, announced that their Phase 3 clinical trial for a combined mRNA vaccine against influenza and COVID-19 did not meet one of the two primary immunogenicity objectives.
The failure to meet one of the primary immunogenicity objectives in a Phase 3 trial is a setback for Pfizer, likely leading to a negative short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80